Since the last decades, there have been numerous reports about the interaction of magnetic field (MF) and cold atmospheric plasma (CAP) with the biological systems, separately. In this manuscript, we have investigated the combined effect of CAP with the static magnetic field (SMF) as an effective method for cancer cells treatment. MDA-MB-231 breast cancer cells were cultured and treated with CAP in different input power and different exposure time in the presence and absence of the SMF. Vitamin C is used in medium, and cell viability is investigated in the presence and absence of this antioxidant compound. The MTT assay has been employed to measure cell survival, and then T-test and one-way ANOVA are used to assess the significance level of quantitative data. In order to determine the migration rate of cancer cells, wound healing assay has been carried out. Results show that presence of the SMF and vitamin C as well as increasing the input power has a significant role on the attenuation of the survival and migration rate of the cells. The results of the present investigation will greatly contribute to improve the CAP efficiency in cancer therapy through using the SMF and vitamin C as a complement to conventional CAP therapies.

Cold atmospheric plasma (CAP) is a 'partially ionized' gas composed of free electrons, positive and negative ions, radicals, excited species, an electric field, and ultraviolet radiation (UVR) [1][2][3][4]. One of the most important advantages of cold plasma is its ability to work at room temperature and atmospheric pressure, which makes it possible to be utilized in biological media with minimal thermal side effects [5][6][7][8]. In this regard, the prominent applications of CAP are microorganism

Recently, cold atmospheric pressure plasmas (CAP) have emerged as a promising oncotherapeutic modality, through physical and chemical effects. Here, for the first time, A2780 CP and SKOV-3 cells, relevant to ovarian cancer and GCs as normal ovarian cells were evaluated through CAP directly, indirectly, and concomitant modality of plasma activated medium (PAM) with common drugs to overcome chemotherapy resistance in ovarian cancer. Our results confirm the high potential and the stronger selectivity of PAM in comparison to CAP for the selected cell lines and selectivity mechanism was related to the pH and concentration of H2O2, NO2 -, and NO3reactive species in the plasma stimulated medium. Compared to the combination of common carboplatin (CAR) and paclitaxel (PTX) chemotherapy treatments, the PAM-based treatment is very promising for ovarian cancer treatment. Our data verify that PAM alone and in combination with carboplatin sensitizes cancer cells to carboplatin, inhibits the SOD1 gene, and selectively induces apoptosis accompanied with high expression of p53, Bax, and activation of Caspase-3.

No abstract